Latest Insider Transactions at Blueprint Medicines Corp (BPMC)
This section provides a real-time view of insider transactions for Blueprint Medicines Corp (BPMC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Blueprint Medicines Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Blueprint Medicines Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 24
2023
|
Jeffrey W. Albers Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+7.28%
|
$15,000
$1.87 P/Share
|
|
Nov 03
2023
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Direct |
1,485
-0.84%
|
$89,100
$60.13 P/Share
|
|
Nov 03
2023
|
Jeffrey W. Albers Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,485
+0.83%
|
$53,460
$36.05 P/Share
|
|
Nov 02
2023
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Direct |
4,634
-1.28%
|
$278,040
$60.71 P/Share
|
|
Nov 02
2023
|
Jeffrey W. Albers Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,634
+2.5%
|
$166,824
$36.05 P/Share
|
|
Nov 01
2023
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Direct |
3,881
-2.16%
|
$232,860
$60.02 P/Share
|
|
Nov 01
2023
|
Jeffrey W. Albers Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,881
+2.11%
|
$139,716
$36.05 P/Share
|
|
Oct 26
2023
|
Christopher K. Murray CHIEF TECHNICAL OPERATIONS |
SELL
Open market or private sale
|
Direct |
600
-2.34%
|
$33,600
$56.4 P/Share
|
|
Oct 04
2023
|
Fouad Namouni PRESIDENT, R & D |
SELL
Open market or private sale
|
Direct |
3,769
-5.72%
|
$180,912
$48.06 P/Share
|
|
Sep 28
2023
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Direct |
6,898
-3.77%
|
$344,900
$50.17 P/Share
|
|
Sep 28
2023
|
Jeffrey W. Albers Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,898
+3.63%
|
$6,898
$1.87 P/Share
|
|
Sep 27
2023
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Direct |
18,102
-3.18%
|
$886,998
$49.76 P/Share
|
|
Sep 27
2023
|
Jeffrey W. Albers Director |
BUY
Exercise of conversion of derivative security
|
Direct |
18,102
+8.53%
|
$18,102
$1.87 P/Share
|
|
Aug 25
2023
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Direct |
10,000
-5.37%
|
$500,000
$50.16 P/Share
|
|
Aug 25
2023
|
Jeffrey W. Albers Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+5.1%
|
$10,000
$1.87 P/Share
|
|
Aug 24
2023
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Direct |
15,000
-7.85%
|
$735,000
$49.57 P/Share
|
|
Aug 24
2023
|
Jeffrey W. Albers Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+7.28%
|
$15,000
$1.87 P/Share
|
|
Jun 21
2023
|
Habib J Dable Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,600
+28.57%
|
-
|
|
Jun 21
2023
|
John Tsai Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,600
+28.57%
|
-
|
|
Jun 21
2023
|
Lynn Seely Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,600
+19.1%
|
-
|
|
Jun 21
2023
|
Mark Alan Goldberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,600
+13.97%
|
-
|
|
Jun 21
2023
|
Jeffrey W. Albers Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,600
+1.46%
|
-
|
|
Jun 21
2023
|
Daniella Beckman Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,600
+23.21%
|
-
|
|
Jun 21
2023
|
Nicholas Lydon |
BUY
Grant, award, or other acquisition
|
Direct |
2,600
+4.45%
|
-
|
|
Jun 21
2023
|
Alexis Borisy Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,600
+3.49%
|
-
|
|
Jun 21
2023
|
Lonnel Coats Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,600
+19.1%
|
-
|
|
Jun 05
2023
|
Percy H. Carter Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,307
-5.71%
|
$119,964
$52.06 P/Share
|
|
Jun 05
2023
|
L. Becker Hewes Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,404
-3.67%
|
$73,008
$52.05 P/Share
|
|
Mar 06
2023
|
Fouad Namouni PRESIDENT, R & D |
SELL
Open market or private sale
|
Direct |
1,948
-1.44%
|
$87,660
$45.04 P/Share
|
|
Mar 06
2023
|
Christina Rossi Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,059
-2.62%
|
$137,655
$45.0 P/Share
|
|
Mar 06
2023
|
Christopher K. Murray CHIEF TECHNICAL OPERATIONS |
SELL
Open market or private sale
|
Direct |
1,875
-3.41%
|
$84,375
$45.0 P/Share
|
|
Mar 06
2023
|
Debra Durso Bumpus Chief People Officer |
SELL
Open market or private sale
|
Direct |
3,158
-2.96%
|
$142,110
$45.0 P/Share
|
|
Mar 06
2023
|
Philina Lee Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,676
-2.55%
|
$75,420
$45.06 P/Share
|
|
Mar 06
2023
|
L. Becker Hewes Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,514
-1.9%
|
$68,130
$45.25 P/Share
|
|
Mar 06
2023
|
Kate Haviland Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
6,640
-2.51%
|
$298,800
$45.19 P/Share
|
|
Mar 06
2023
|
Ariel Hurley Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,126
-3.69%
|
$50,670
$45.06 P/Share
|
|
Mar 06
2023
|
Michael Landsittel Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,007
-2.92%
|
$135,315
$45.1 P/Share
|
|
Mar 06
2023
|
Tracey L Mc Cain EVP & Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,322
-2.97%
|
$149,490
$45.07 P/Share
|
|
Mar 06
2023
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Direct |
9,793
-2.68%
|
$430,892
$45.0 P/Share
|
|
Mar 06
2023
|
Percy H. Carter Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
761
-0.92%
|
$34,245
$45.25 P/Share
|
|
Mar 01
2023
|
Percy H. Carter Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+23.28%
|
-
|
|
Mar 01
2023
|
Philina Lee Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+27.56%
|
-
|
|
Mar 01
2023
|
Debra Durso Bumpus Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+18.99%
|
-
|
|
Mar 01
2023
|
Michael Landsittel Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+19.52%
|
-
|
|
Mar 01
2023
|
L. Becker Hewes Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+23.9%
|
-
|
|
Mar 01
2023
|
Ariel Hurley Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,425
+26.17%
|
-
|
|
Mar 01
2023
|
Christina Rossi Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+20.43%
|
-
|
|
Mar 01
2023
|
Kate Haviland Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+23.22%
|
-
|
|
Mar 01
2023
|
Fouad Namouni PRESIDENT, R & D |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+18.12%
|
-
|
|
Mar 01
2023
|
Christopher K. Murray CHIEF TECHNICAL OPERATIONS |
BUY
Grant, award, or other acquisition
|
Direct |
8,750
+24.09%
|
-
|